Výsledky vyhledávání - "Cara, Cassino"

Akademický článek

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires

Autor: Melissa J. Karau, Jay Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel

Publikováno v: BMC Research Notes, Vol 16, Iss 1, Pp 1-5 (2023)

Abstract Orthopedic foreign body-associated infection can be difficult to treat due to the formation of biofilms protecting microorganisms from both antimicrobials and the immune system. Exebacase is an antistaphylococcal lysin (cell wall hydrolase)

Externí odkaz: https://doaj.org/article/bcc21f6ce9994321aedb1b16301e5b48

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Autor: Raymond Schuch, Cara Cassino, Xavier Vila-Farres

Publikováno v: Frontiers in Microbiology, Vol 13 (2022)

Direct lytic agents (DLAs) are novel antimicrobial compounds with unique mechanisms of action based on rapid cell wall destabilization and bacteriolysis. DLAs include two classes of purified polypeptides—lysins (peptidoglycan hydrolase enzymes) and

Externí odkaz: https://doaj.org/article/19bcc302452a4a03a49f4508beb63841

Zobrazit plný text záznamu

Akademický článek

Arthroscopic 'Debridement and Implant Retention' With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection

Autor: Tristan Ferry, Cécile Batailler, Aubin Souche, Cara Cassino, Christian Chidiac, Thomas Perpoint, Claire le Corvaisier, Jérôme Josse, Romain Gaillard, Julien Roger, Camille Kolenda, Sébastien Lustig, Frédéric Laurent, The Lyon BJI Study Group

Publikováno v: Frontiers in Medicine, Vol 8 (2021)

Exebacase, a recombinantly produced lysin has recently (i) reported proof-of-concept data from a phase II study in S. aureus bacteremia and (ii) demonstrated antibiofilm activity in vitro against S. epidermidis. In patients with relapsing multidrug-r

Externí odkaz: https://doaj.org/article/fdf63ee9ae104a9d8c644caab5dd38ee

Zobrazit plný text záznamu

991. Single Center, Exploratory, Open-label Prospective Study Using the Minimally Invasive LysinDAIR Procedure (Lysin Administration During an Arthroscopic DAIR Procedure) in Patients with Suspected Relapsing Chronic Coagulase-Negative Staphylococci (CNS) Prosthetic Hip Infection (PHI)

Autor: Tristan Ferry, Anne Conrad, Camille Kolenda, Frederic Laurent, Axel Schmidt, Cara Cassino, Sebastien Lustig, Cécile Batailler

Publikováno v: Open Forum Infectious Diseases. 9

Background Exebacase, a recombinant staphylococcal lysin, has: (i) reported proof-of-concept data in Phase II in S. aureus bacteremia; (ii) demonstrated antibiofilm activity in vitro against S. epidermidis; and (iii) been used as salvage therapy in 4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9ede6efad15d6853ba41fdebeb54175c
https://doi.org/10.1093/ofid/ofac492.833

Zobrazit plný text záznamu

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Autor: Melissa Karau, Suzannah Schmidt-Malan, Jay Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel

Introduction: Staphylococcus aureus is the most common cause of orthopedic infections and can be challenging to treat, especially in the presence of a foreign body. The antistaphylococcal lysins exebacase and CF-296 have rapid bactericidal activity,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743fdd002bbaf06b033498ed5043713a
https://jbji.copernicus.org/articles/7/169/2022/

Zobrazit plný text záznamu

Correction for Oh et al., 'Development of a Broth Microdilution Method for Exebacase Susceptibility Testing'

Autor: Jane E. Ambler, Jun T. Oh, Cara Cassino, Raymond Schuch

Publikováno v: Antimicrobial Agents and Chemotherapy

Exebacase (CF-301) belongs to a new class of protein-based antibacterial agents, known as lysins (peptidoglycan hydrolases). Exebacase, a novel lysin with antistaphylococcal activity, is in phase 3 of clinical development. To advance into the clinic,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::001b3640c4e55af367c96caa306fb3b1
https://doi.org/10.1128/aac.01658-21

Zobrazit plný text záznamu

Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection

Autor: Ganga S Moorthy, Rachel G Greenberg, Chi D Hornik, Cara Cassino, Parviz Ghahramani, Karan R Kumar, Vance G Fowler, Michael Cohen-Wolkowiez

Publikováno v: Clin Infect Dis

Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3f799bb55f313f6a2e4ba964076a38e
https://pubmed.ncbi.nlm.nih.gov/34894129

Zobrazit plný text záznamu

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Autor: Cara Cassino, Raymond Schuch, Steven M Swift, Karen Sauve

Publikováno v: Antimicrobial Agents and Chemotherapy. 65

Exebacase (CF-301) is a novel antistaphylococcal lysin (cell wall hydrolase) in phase 3 of clinical development for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis, used in addition to standard-of-care antibiotic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21440c4a2990f0554ff4eb3f1afe4a1f
https://doi.org/10.1128/aac.02723-20

Zobrazit plný text záznamu